In the world of cardiovascular nutrition, 2,000 FU (Fibrinolytic Units) is the globally recognized baseline for daily intake. However, at nattiase®, we believe that understanding the dose-response curve is not about promoting "higher is always better." Instead, it is about empowering formulators to choose the right dose for the right goal, while remaining strictly within regional regulatory frameworks.

The Foundation: 2,000 FU for General Wellness

For the vast majority of consumers seeking long-term circulatory support, 2,000 FU is an exceptional and sufficient dosage.

．Evidence: Studies by Kim et al. (2008) and Kurosawa et al. (2015) confirm that 2,000 FU is highly effective for supporting healthy blood pressure and maintaining natural anticoagulant balance.
．Compliance: In many regions (such as parts of Europe), regulatory bodies have specific guidelines or limits for Nattokinase intake. 2,000 FU remains the "gold standard" for compliance and steady-state effectiveness.

Targeted Support: The 4,000 FU Tier

When a product is designed for a more specific clinical intent, such as managing fibrinogen levels, research indicates a dose-dependent response.

．Evidence: Hsia et al. (2009) demonstrated that 4,000 FU daily significantly impacts fibrinogen and coagulation factors. Conversely, in Ren et al. (2022), while the 3,600 FU group showed some impact on lipids, it did not achieve statistically significant results in reducing plaque size compared to the higher-dose group.
．Compliance: Key Insight – The Impact of Variables: These contrasting findings underscore that clinical results are heavily influenced by trial design, subject baseline conditions, and the specific source of Nattokinase used. Consequently, purely relying on dosage figures without considering these experimental differences may lead to varying interpretations of efficacy.

Intensive Intervention: Data on 10,000+ FU

For specialized arterial maintenance, large-scale trials like Ren et al. (2022) showed that 10,800 FU achieved significant results in plaque reduction. While this data showcases the broad potential of the enzyme, it represents a targeted intervention rather than a standard for every consumer.

Important Note: Scientific data on high dosages serves to demonstrate the biological potential of the enzyme. It is not an endorsement that "more is always better." Formulations must always prioritize safety, local regulations, and the specific needs of the target audience.

The nattiase® Advantage: Flexibility, Not Just Potency

nattiase® offers raw material specifications ranging from 20,000 FU/g to 60,000 FU/g. Our objective is to provide formulation flexibility:

．Evidence: Optimized Delivery: High-spec ingredients like our 60,000 FU/g allow brands to encapsulate a standard 2,000 FU dose into very small, consumer-friendly capsules.
．Compliance-Ready: Our diverse range supports both "Foundational" products that adhere to strict regulatory caps and "Intensive" products designed for markets with higher dietary limits.

Conclusion

The true value of Nattokinase lies in its ability to be precisely calibrated. The most successful products are those that balance clinical data, safety by Lampe & English (2016), regional law, and consumer intent. By utilizing nattiase, brands can define their potency scientifically and responsibly.

References

Kim et al., “Effects of nattokinase on blood pressure: a randomized, controlled trial.”, 2008 (doi: https://doi.org/10.1291/hypres.31.1583.)

Hsia et al., “Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII. ”, 2009 (doi: https://doi.org/10.1016/j.nutres.2009.01.009)

Kurosawa et al., “A single-dose of nattokinase potentiates thrombolysis and anti-coagulation profiles. ”, 2015 (doi: https://doi.org/10.1038/srep11601)

Lampe, B. J., & English, J. C., “Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto.”, 2016 (doi: https://doi.org/10.1016/j.fct.2015.12.025)

Ren et al., “Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.”, 2022 (doi: https://doi.org/10.3389/fcvm.2022.964977)